CA
CALA.US Calithera Biosciences Inc
- Market cap
- USD 1.46K
- P/E
- -
- P/B
- 0.07x
- ROE
- -92.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is CALA.US undervalued?
Graham numberThe Graham number of Calithera Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Calithera Biosciences Inc fundamental analysis
No fundamental analysis for Calithera Biosciences Inc yet.
Calithera Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Calithera Biosciences Inc
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Full company profileCalithera Biosciences Inc financial statements
Calithera Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 9.00K | 0.00 | 0.00 | 26.0M | 22.3M | 0.00 | 0.00 | 9.75M | 0.00 |
| Gross Profit | - | 9.00K | -23.7M | -27.7M | 26.0M | 22.3M | -76.3M | -1.87M | 8.32M | -1.39M |
| Operating Income | -12.4M | -21.7M | -32.8M | -38.3M | -29.7M | -57.3M | -92.9M | -91.4M | -114M | -42.1M |
| EBITDA | -12.1M | -21.4M | -32.4M | -38.0M | -29.3M | -56.8M | -92.4M | -91.0M | -115M | -39.4M |
| Net Income | -12.4M | -21.7M | -32.6M | -38.0M | -27.8M | -51.5M | -86.3M | -88.5M | -115M | -18.9M |
| EPS | -31 | -93 | -36 | -39 | -17 | -28 | -37 | -26 | -31 | -3.78 |
| Balance Sheet | ||||||||||
| Total Assets | 34.8M | 105M | 75.8M | 54.8M | 192M | 143M | 169M | 126M | 64.8M | 28.7M |
| Total Liabilities | 55.7M | 4.40M | 3.96M | 4.89M | 42.1M | 16.0M | 26.3M | 23.2M | 56.4M | 8.28M |
| Shareholders' Equity | -20.8M | 100M | 71.8M | 49.9M | 150M | 127M | 142M | 102M | 8.38M | 20.4M |
| Cash & Short-term Investments | 33.8M | 102M | 71.9M | 51.8M | 186M | 136M | 157M | 115M | 59.5M | 25.5M |
| Total Debt | - | - | - | - | - | - | 8.20M | 6.72M | 43.7M | 1.67M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -11.8M | -19.2M | -29.9M | -31.0M | 13.8M | -64.8M | -78.7M | -84.3M | -66.3M | -43.6M |
| Capital Expenditure | 164K | 556K | 441K | 401K | 1.23M | 214K | 7.00K | 61.0K | 147K | 133K |
| Free Cash Flow | -12.0M | -19.8M | -30.4M | -31.4M | 12.5M | -65.1M | -78.8M | -84.4M | -66.4M | -43.7M |
| Ratios | ||||||||||
| ROE | - | -21.6% | -45.5% | -76.2% | -18.5% | -40.6% | -60.6% | -86.5% | -1,373.0% | -92.5% |
| ROA | -35.5% | -20.7% | -43.1% | -69.4% | -14.5% | -36.1% | -51.2% | -70.5% | -177.7% | -65.8% |
| Net Profit Margin | - | -241,244.4% | - | - | -107.2% | -231.3% | - | - | -1,180.4% | - |
| Debt to Equity | - | - | - | - | - | - | 0.06x | 0.07x | 5.22x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Calithera Biosciences Inc dividends
Calithera Biosciences Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:20 on Jun 15, 2022.
Who owns Calithera Biosciences Inc
Top funds holding CALA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard US Opportunities Ins USD Acc | 15.7K | 0.32% | -61.01% | Mar 2023 |
| JHVIT Total Stock Market Index I | 171.00 | 0.00% | 0.00% | Apr 2023 |
Top institutions holding CALA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FinTrust Capital Advisors, LLC | 1.20K | 0.02% | 0.00% | Mar 2023 |
| Bvf Inc | 0.00 | 0.00% | -100.00% | Mar 2023 |
| State Street Corporation | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Acadian Asset Management LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Mar 2023 |
| BNP Paribas Arbitrage, SA | 0.00 | 0.00% | -100.00% | Dec 2022 |
| TSP Capital Management Group/LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Coppell Advisory Solutions LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Coppell Advisory Solutions Corp. | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Arcus Capital Partners LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Mar 2023 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Quent Capital, LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Group One Trading, LP | 0.00 | 0.00% | -100.00% | Mar 2023 |
| PRIMECAP Management Company | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Truvestments Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
Calithera Biosciences Inc company profile
- Company name
- Calithera Biosciences Inc
- Ticker
- CALA.US
- Exchange
- USA Stocks
- Listed since
- Oct 2, 2014
- Sector
- Financial Services
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 343 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 870 1000
- Website
- calithera.com
About Calithera Biosciences Inc
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Calithera Biosciences Inc management
3- Ms. Stephanie Wong CPACFO & Secretary · born 1975
- Dr. Christopher J. Molineaux Ph.D.Senior Vice President of Development · born 1953
- Mr. Frank Parlati Ph.D.Senior Vice President of Research · born 1969